---
title: "JT released its first-quarter performance, with a net profit attributable to the parent company of 24.7586 million yuan, an increase of 137.33%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238059770.md"
description: "JT released its performance for the first quarter of 2025, with operating revenue of 155 million yuan, a year-on-year increase of 21.26%. The net profit attributable to the parent company was 24.7586 million yuan, a year-on-year increase of 137.33%; the net profit after deducting non-recurring gains and losses was 25.0382 million yuan, a year-on-year increase of 171.09%. The basic earnings per share were 0.1 yuan"
datetime: "2025-04-29T12:44:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238059770.md)
  - [en](https://longbridge.com/en/news/238059770.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238059770.md)
generator: "portal-rs"
---

# JT released its first-quarter performance, with a net profit attributable to the parent company of 24.7586 million yuan, an increase of 137.33%

According to the Zhitong Finance APP, JT (300400.SZ) released its first-quarter report for 2025, with operating revenue of 155 million yuan, a year-on-year increase of 21.26%. The net profit attributable to shareholders of the listed company was 24.7586 million yuan, a year-on-year increase of 137.33%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.0382 million yuan, a year-on-year increase of 171.09%. The basic earnings per share were 0.1 yuan

### Related Stocks

- [300400.CN](https://longbridge.com/en/quote/300400.CN.md)

## Related News & Research

- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)
- [Fibocom wins China antitrust clearance for 37.16% Hangsheng Electronics stake purchase](https://longbridge.com/en/news/296214384.md)
- [Borderless.xyz Deepens Africa Coverage as CrissCross Goes Live on Its Network](https://longbridge.com/en/news/296234613.md)
- [Celesc board signs off on Q2 2026 interim financial statements](https://longbridge.com/en/news/296404844.md)
- [Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety](https://longbridge.com/en/news/296374826.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**